



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|--|
| (51) International Patent Classification: A61K 31/00 | A2 | (11) International Publication Number: WO 00/02548 (43) International Publication Date: 20 January 2000 (20.01.2000) |
| (21) International Application Number: PCT/US99/15533 (22) International Filing Date: 09 July 1999 (09.07.1999) (30) Priority Data: 09/113,947 10 July 1998 (10.07.1998) US (60) Parent Application or Grant OSTEOSCREEN [/]; (). MUNDY, Gregory, R. [/]; (). GARRETT, I., Ross [/]; (). ROSSINI, G. [/]; (). MUNDY, Gregory, R. [/]; (). GARRETT, I., Ross [/]; (). ROSSINI, G. [/]; (). MURASHIGE, Kate ; (). | | Published |
| (54) Title: INHIBITORS OF PROTEASOMAL ACTIVITY FOR STIMULATING BONE AND HAIR GROWTH (54) Titre: INHIBITEURS D'ACTIVITE PROTEASOMIQUE POUR LA STIMULATION DE LA CROISSANCE OSSEUSE ET CAPILLAIRE (57) Abstract <p>Compounds that inhibit the activity of NF-'kappa'B or inhibit the activity of the proteasome or both promote bone formation and hair growth and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation; they also stimulate the production of hair follicles and are thus useful in stimulating hair growth, including hair density, in subject where this is desirable.</p> (57) Abrégé <p>L'invention concerne des composés qui inhibent l'activité de NF-'kappa'B ou l'activité protéasomique ou qui stimulent à la fois la formation osseuse et la croissance capillaire. Par conséquent, ces composés sont utiles dans le traitement de l'ostéoporose, des fractures ou déficiences osseuses, de l'hyperparathyroïdie primaire ou secondaire, des parodontopathies, des troubles osseux métastatiques, des maladies ostéolytiques, des états suivant la chirurgie plastique et la chirurgie d'implantation de prothèses d'articulation ainsi que des états suivant les implantations dentaires. Ces composés sont également utiles pour stimuler la production des follicules capillaires et donc la croissance capillaire, y compris la densité capillaire, chez les sujets pour lesquels un tel traitement est souhaitable.</p> | | |

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|--|
| (51) International Patent Classification ⁶ : A61K 31/00 | A2 | (11) International Publication Number: WO 00/02548 (43) International Publication Date: 20 January 2000 (20.01.00) |
| (21) International Application Number: PCT/US99/15533 (22) International Filing Date: 9 July 1999 (09.07.99) (30) Priority Data: 09/113,947 10 July 1998 (10.07.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/113,947 (CON) Filed on 10 July 1998 (10.07.98) (71) Applicant (for all designated States except US): OSTEO-SCREEN [US/US]; Suite 201, 2040 Babcock Road, San Antonio, TX 78229 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): MUNDY, Gregory, R. [US/US]; 3719 Morgan's Creek, San Antonio, TX 78230 (US). GARRETT, I., Ross [US/US]; 16729 Windjammer, San Antonio, TX 78023 (US). ROSSINI, G. [US/US]; 5827 N.W. Loop 410 #1224, San Antonio, TX 78238 (US). | | (74) Agents: MURASHIGE, Kate et al.; Morrison & Foerster LLP, 2000 Pennsylvania Avenue, N.W., Washington, DC 20006-1888 (US). (81) Designated States: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SD, SG, SI, SK, TR, TT, US, UZ, VN, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i> |
| (54) Title: INHIBITORS OF PROTEASOMAL ACTIVITY FOR STIMULATING BONE AND HAIR GROWTH | | |
| (57) Abstract Compounds that inhibit the activity of NF- κ B or inhibit the activity of the proteasome or both promote bone formation and hair growth and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation; they also stimulate the production of hair follicles and are thus useful in stimulating hair growth, including hair density, in subject where this is desirable. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

Description

5

10

15

20

25

30

35

40

45

50

55

INHIBITORS OF PROTEASOMAL ACTIVITY FOR STIMULATING BONE AND HAIR GROWTH

Technical Field

The invention relates to compositions and methods for use in treating skeletal system disorders in a vertebrate at risk for bone loss, and in treating conditions that are characterized by the need for bone growth, in treating fractures, and in treating cartilage disorders. The invention also relates to enhancing hair density and growth. More specifically, the invention concerns the use of inhibitors of proteasomal activity and inhibitors of NF- κ B activity for these purposes.

Background Art

Inhibitors of proteasomal activity, and to some extent inhibitors of NF- κ B activity, have two important physiological effects. First, they are able to enhance bone formation and are thus useful for treating various bone disorders. Second, they stimulate the production of hair follicles and are thus useful in stimulating hair growth, including hair density, in subject where this is desirable.

Effect on Bone

Bone is subject to constant breakdown and resynthesis in a complex process mediated by osteoblasts, which produce new bone, and osteoclasts, which destroy bone. The activities of these cells are regulated by a large number of cytokines and growth factors, many of which have now been identified and cloned.

There is a plethora of conditions which are characterized by the need to enhance bone formation or to inhibit bone resorption. Perhaps the most obvious is the case of bone fractures, where it would be desirable to stimulate bone growth and to hasten and complete bone repair. Agents that enhance bone formation would also be useful in facial reconstruction procedures. Other bone deficit conditions include bone segmental defects, periodontal disease, metastatic bone disease, osteolytic bone disease and conditions where connective tissue repair would be beneficial, such as healing or regeneration of cartilage defects or injury. Also of great significance is the chronic condition of osteoporosis, including age-related osteoporosis and osteoporosis associated with post-menopausal

5 hormone status. Other conditions characterized by the need for bone growth include
primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related
osteoporosis, and glucocorticoid-related osteoporosis.

10 There are currently no satisfactory pharmaceutical approaches to managing any of
5 these conditions. Bone fractures are still treated exclusively using casts, braces,
anchoring devices and other strictly mechanical means. Further bone deterioration
associated with post-menopausal osteoporosis has been treated with estrogens or
15 bisphosphonates, which may have drawbacks for some individuals. Although various
approaches have been tried, as further discussed below, there remains a need for additions
10 to the repertoire of agents which can be used to treat these conditions.

20 Treatment of bone or other skeletal disorders, such as those associated with
cartilage, can be achieved either by enhancing bone formation or inhibiting bone
resorption or both. A number of approaches have been suggested which relate to bone
formation.

25 Bone tissue is an excellent source for factors which have the capacity for
stimulating bone cells. Thus, extracts of bovine bone tissue obtained from
slaughterhouses contain not only structural proteins which are responsible for maintaining
the structural integrity of bone, but also biologically active bone growth factors which can
30 stimulate bone cells to proliferate. Among these latter factors are transforming growth
20 factor β , the heparin-binding growth factors (e.g., acidic and basic fibroblast growth
factor), the insulin-like growth factors (e.g., insulin-like growth factor I and insulin-like
growth factor II), and a recently described family of proteins called bone morphogenetic
35 proteins (BMPs). All of these growth factors have effects on other types of cells, as well
as on bone cells.

25 The BMPs are novel factors in the extended transforming growth factor β
superfamily. Recombinant BMP2 and BMP4 can induce new bone formation when they
40 are injected locally into the subcutaneous tissues of rats (Wozney *J Molec Reprod Dev*
(1992) 32:160-67). These factors are expressed by normal osteoblasts as they
differentiate, and have been shown to stimulate osteoblast differentiation and bone nodule
45 formation *in vitro* as well as bone formation *in vivo* (Harris S. *et al. J Bone Miner Res*
30 (1994) 9:855-63). This latter property suggests potential usefulness as therapeutic agents
in diseases which result in bone loss.

50

55

5 The cells which are responsible for forming bone are osteoblasts. As osteoblasts
differentiate from precursors to mature bone-forming cells, they express and secrete a
number of enzymes and structural proteins of the bone matrix, including Type-1 collagen,
osteocalcin, osteopontin and alkaline phosphatase. They also synthesize a number of
10 growth regulatory peptides which are stored in the bone matrix, and are presumably
responsible for normal bone formation. These growth regulatory peptides include the
BMPs (Harris S. *et al.* (1994), *supra*). In studies of primary cultures of fetal rat calvarial
osteoblasts, BMPs 1, 2, 3, 4, and 6 are expressed by cultured cells prior to the formation
15 of mineralized bone nodules (Harris S. *et al.* (1994), *supra*). Like alkaline phosphatase,
osteocalcin and osteopontin, the BMPs are expressed by cultured osteoblasts as they
proliferate and differentiate.

20 Although the BMPs are potent stimulators of bone formation *in vitro* and *in vivo*,
there are disadvantages to their use as therapeutic agents to enhance bone healing.
Receptors for the bone morphogenetic proteins have been identified in many tissues, and
25 the BMPs themselves are expressed in a large variety of tissues in specific temporal and
spatial patterns. This suggests that BMPs may have effects on many tissues in addition to
bone, potentially limiting their usefulness as therapeutic agents when administered
systemically. Moreover, since they are peptides, they would have to be administered by
30 injection. These disadvantages impose severe limitations to the development of BMPs as
therapeutic agents.

35 The fluorides, suggested also for this purpose, have a mode of action which may
be related to tyrosine phosphorylation of growth factor receptors on osteoblasts, as
described, for example, Burgener *et al.* *J Bone Min Res* (1995) 10:164-171, but
administration of fluorides is associated with increased bone fragility, presumably due to
25 effects on bone mineralization.

40 Small molecules which are able to stimulate bone formation have been disclosed
in PCT applications WO98/17267 published 30 April 1998, WO97/15308 published
1 May 1997 and WO97/48694 published 24 December 1997. These agents generally
comprise two aromatic systems spatially separated by a linker. In addition, PCT
45 application WO98/25460 published 18 June 1998 discloses the use of the class of
compounds known as statins in enhancing bone formation. U.S. application Serial No.
09/096,631 filed 12 June 1998 is directed to compounds for stimulating bone growth that
50

5 are generally isoprenoid pathway inhibitors. The contents of this application, as well as that of the PCT applications cited above, are incorporated herein by reference.

10 Other agents appear to operate by preventing the resorption of bone. Thus, U.S. Patent No. 5,280,040 discloses compounds described as useful in the treatment of
5 osteoporosis. These compounds putatively achieve this result by preventing bone resorption.

15 Wang, G.-J. *et al.*, *J Formos Med Assoc* (1995) 94:589-592 report that certain lipid clearing agents, exemplified by lovastatin and bezafibrate, were able to inhibit the bone resorption resulting from steroid administration in rabbits. There was no effect on
10 bone formation by these two compounds in the absence of steroid treatment. The mechanism of the inhibition in bone resorption observed in the presence of steroids (and
20 the mechanism of the effect of steroid on bone *per se*) is said to be unknown.

25 An abstract entitled "Lovastatin Prevents Steroid-Induced Adipogenesis and Osteoporosis" by Cui, Q. *et al.* appeared in the Reports of the ASBMR 18th Annual Meeting (September 1996) *J Bone Mineral Res.* (1996) 11(S1):S510 which reports that
15 lovastatin diminished triglyceride vesicles that accumulated when osteoprogenitor cells cloned from bone marrow stroma of chickens were treated in culture with dexamethasone. Lovastatin was reported to diminish the expression of certain mRNAs
30 and to allow the cells to maintain the osteogenic phenotype after dexamethasone treatment, and chickens that had undergone bone loss in the femoral head as a result of dexamethasone treatment were improved by treatment with lovastatin.

35 These data are, however, contrary to reports that dexamethasone and other inducers, such as BMPs, induce osteoblastic differentiation and stimulate osteocalcin mRNA (Bellows, C.G., *et al.*, *Develop Biol* (1990) 140:132-38; Rickard, D.J., *et al.*,
25 *Develop Biol* (1994) 161:218-28). In addition, Ducy, P. *et al.*, *Nature* (1996) 382:448-52 have recently reported that osteocalcin deficient mice exhibit a phenotype marked by
40 increased bone formation and bones of improved functional quality, without impairment of bone resorption. Ducy *et al.* state that their data suggest that osteocalcin antagonists may be of therapeutic use in conjunction with estrogen replacement therapy (for
45 prevention or treatment of osteoporosis).
30

50 It has also been shown that lovastatin inhibits lipopolysaccharide-induced NF- κ B activation in human mesangial cells. Guijaro, C. *et al.* *Nephrol Dial Transplant* (1996) 11:6:990-996.

And Its Effect on Hair Growth

Disorders of human hair growth include male pattern baldness, alopecia areata, alopecia induced by cancer chemotherapy and hair thinning associated with aging. These conditions are poorly understood, but nevertheless common and distressing, since hair is an important factor in human social and sexual communication.

Hair follicle regulation and growth are still not well understood, but represent dynamic processes involving proliferation, differentiation and cellular interactions during tissue morphogenesis. It is believed that hair follicles are formed only in early stages of development and not replaced.

Hardy, M.H. *et al. Trans Genet* (1992) 8:55-61 describes evidence that bone morphogenetic proteins (BMPs), members of the TGF β super family, are differentially expressed in hair follicles during development. Harris, S.E. *et al. J Bone Miner Res* (1994) 9:855-863 describes the effects of TGF β on expression of BMP-2 and other substances in bone cells. BMP-2 expression in mature follicles also occurs during maturation and after the period of cell proliferation (Hardy *et al.* (1992, *supra*). As noted, however, by Blessing, M. *et al. Genes and Develop* (1992) 7:204-215, the precise role functional role of BMP-2 in hair follicle maturation remains unclear.

Approaches to treat baldness abound in the U.S. patent literature. See for example U.S. Patent No. 5,767,152 (cyanocarboxylic acid derivatives), U.S. Patent No. 5,824,643 (keratinocyte growth factors) and U.S. Patent No. 5,910,497 (16-pyrazinyl-substitute-4-aza-androstane 5-alpha.-reductase isozyme 1 inhibitors). There are many others.

Gat, U. *et al. Cell* (1998) 95:605-614 has demonstrated that β -catenin causes adult epithelial cells to create hair follicles, a surprising result in light of the known inability of mature cells to do so. B-Catenin is known to play a role in cell-cell adhesion and growth factor signal transfection. It is also known that after ubiquitination, β -catenin is degraded by the proteasomes. Orford, K. *et al. J Biol Chem* (1997) 272:24735-24738. At least one gene associated with hair growth (or lack thereof) has also been reported. Ahmed, W. *et al. Science* (1998) 279:720-724.

Two accepted agents currently used for the treatment of hair loss are the antihypertensive drug Minoxidil and the 5 α -reductase inhibitor Finasteride. Neither is entirely satisfactory. Both suffer from modest efficacy and are inconvenient to

5 administer. A specific, topically active and easy to administer compound with better efficacy than these agents would represent a marked advance.

10 Proteasomes and NF- κ B

5 The present invention discloses convenient assays for compounds that will be useful in the treatment of bone disorders and in stimulating hair growth. The assays involve inhibition of the activity of the transcription factor NF- κ B or of the activity of
15 proteasomal proteases, preferably proteasomal proteases. Compounds which inhibit these activities are generally useful in treating bone and hair growth disorders. Compounds that
10 inhibit the production of the transcription factor and these proteases will also be useful in the invention. Their ability to do so can be further confirmed by additional assays.

20 The proteasome is a noncompartmentalized collection of unrelated proteases which form a common architecture in which proteolytic subunits are self-assembled to form barrel-shaped complexes (for review, see Baumeister *et al.*, *Cell* (1998) 92:367-380.
25 The proteasome contains an array of distinct proteolytic activities inside eukaryotic cells. Compounds which inhibit proteasomal activity also reduce NF- κ B activity by limiting its capacity to be translocated to the nucleus (Barnes, P.J. *et al. New Engl J Med* (1997) 336:1066-1071.

30 Disclosure of the Invention

20 The present invention adds to the repertoire of osteogenic and hair growth
35 stimulating agents by providing drugs which would inhibit key proteins and enzymes involved in proteasomal activity and which decrease the activity of the nuclear transcription factor NF- κ B, and thus stimulate bone and hair growth. In accordance with
25 the present invention, we have discovered that inhibition of the functions of the
40 proteasomal proteins and the transcription factor NF- κ B in bone cells leads to increased bone growth and to hair follicle formation and stimulation. Thus, assessing a candidate compound for its ability to inhibit proteasomal proteins or NF- κ B provides a useful
45 means to identify bone and hair growth anabolic agents.

30 The present specification thus provides methods for identification of osteogenic compounds to stimulate bone growth and compounds that stimulate hair growth by assessing their capacity to inhibit proteasome activity or to inhibit the activity of the
50 transcription factor NF- κ B, preferably to inhibit proteasomal activity. Also useful in the

5 methods of the invention are compounds which inhibit the *in situ* production of the
enzymes contained in the proteasome or inhibit the production of NF- κ B, preferably of
enzymes of the proteasomes. Once a compound found to inhibit these activities has been
10 identified, it can be used in an additional aspect of the invention -- a method to stimulate
5 the growth of bone or of hair by contacting suitable cells with the identified compound.
The cellular contact may include *in vivo* administration and the compounds of the
invention are thus useful in treating degenerative bone diseases, fractures, dental
15 problems, baldness, alopecia and the like. These methods are performed, according to the
present invention, with compounds identified as inhibitors of proteasome activity or
10 inhibitors of the activity of transcription factor NF- κ B, preferably inhibitors of the
proteasome enzymes, or inhibitors of the production of the proteasome enzymes or of
20 NF- κ B, preferably of the proteasome enzymes.

Brief Description of the Drawings

25 15 Figure 1 shows a diagram of the isoprenoid pathway.

Modes of Carrying Out the Invention

30 In accordance with the present invention, there are provided methods of treating
bone defects (including osteoporosis, fractures, osteolytic lesions and segmental bone
20 defects) in subjects suffering therefrom said method comprising administering to said
subject, in an amount sufficient to stimulate bone growth, a compound which inhibits
35 proteasomal activity and function or the activity of the nuclear transcription factor NF- κ B
or the production of these proteins.

Also in accordance with the present invention, there are provided methods of
25 treating disorders of hair growth. Disorders of hair growth may be the result of a defect
40 in the ability of existing hair follicles to extrude hair, or may be the result of a deficiency
in the number of hair follicles *per se*. "Stimulation of hair growth" refers to increasing
the volume of hair in a particular area of a subject whether this is the result of an
45 increased rate of growth in length and/or thickness from the same number of hair
30 follicles, growth proceeding from an enhanced number of hair follicles, or both. The
number of hair follicles can be enhanced by further activating existing hair follicles or by
stimulating the appearance or proliferation of hair follicles in a particular region of the
50 skin.

5 As employed herein, the term "subject" embraces human as well as other animal
species, such as, for example, canine, feline, bovine, porcine, rodent, and the like. It will
be understood by the skilled practitioner that the subject is one appropriate to the
10 desirability of stimulating bone growth or hair growth. Thus, in general, for example,
5 stimulation of hair growth will be confined in most instances to animals that would
appropriately exhibit such growth.

15 As used herein, "treat" or "treatment" include a postponement of development of
bone deficit symptoms and/or a reduction in the severity of such symptoms that will or
are expected to develop. These terms further include ameliorating existing bone or
10 cartilage deficit symptoms, preventing additional symptoms, ameliorating or preventing
the underlying metabolic causes of symptoms, preventing or reversing bone resorption
20 and/or encouraging bone growth. Thus, the terms denote that a beneficial result has been
conferred on a vertebrate subject with a cartilage, bone or skeletal deficit, or with the
potential to develop such deficit.

25 By "bone deficit" is meant an imbalance in the ratio of bone formation to bone
resorption, such that, if unmodified, the subject will exhibit less bone than desirable, or
the subject's bones will be less intact and coherent than desired. Bone deficit may also
result from fracture, from surgical intervention or from dental or periodontal disease. By
30 "cartilage defect" is meant damaged cartilage, less cartilage than desired, or cartilage that
20 is less intact and coherent than desired. "Bone disorders" includes both bone deficits and
cartilage defects.

35 Representative uses of the compounds identified by the assay of the invention
include: repair of bone defects and deficiencies, such as those occurring in closed, open
and non-union fractures; prophylactic use in closed and open fracture reduction;
25 promotion of bone healing in plastic surgery; stimulation of bone ingrowth into non-
cemented prosthetic joints and dental implants; elevation of peak bone mass in pre-
40 menopausal women; treatment of growth deficiencies; treatment of periodontal disease
and defects, and other tooth repair processes; increase in bone formation during
distraction osteogenesis; and treatment of other skeletal disorders, such as age-related
45 osteoporosis, post-menopausal osteoporosis, glucocorticoid-induced osteoporosis or
30 disuse osteoporosis and arthritis, or any condition that benefits from stimulation of bone
formation. The compounds of the present invention can also be useful in repair of
50 congenital, trauma-induced or surgical resection of bone (for instance, for cancer

5 treatment), and in cosmetic surgery. Further, the compounds of the present invention can be used for limiting or treating cartilage defects or disorders, and may be useful in wound healing or tissue repair.

10 Conditions which would be benefited by "treating" or "treatment" for stimulation of hair growth include male pattern baldness, alopecia caused by chemotherapy, hair thinning resulting from aging, genetic disorders which result in deficiency of hair coverage, and, in animals, providing additional protection from cold temperatures. Thus, 15 while use in humans may be primarily of cosmetic benefit, use in animals may be therapeutic as well.

10 The compositions of the invention may be administered systemically or locally. For systemic use, the compounds herein are formulated for parenteral (e.g., intravenous, 20 subcutaneous, intramuscular, intraperitoneal, intranasal or transdermal) or enteral (e.g., oral or rectal) delivery according to conventional methods. Intravenous administration can be by a series of injections or by continuous infusion over an extended period.

25 Administration by injection or other routes of discretely spaced administration can be performed at intervals ranging from weekly to once to three times daily. Alternatively, the compounds disclosed herein may be administered in a cyclical manner (administration of disclosed compound; followed by no administration; followed by administration of 30 disclosed compound, and the like). Treatment will continue until the desired outcome is achieved. In general, pharmaceutical formulations will include a compound of the present invention in combination with a pharmaceutically acceptable vehicle, such as 35 saline, buffered saline, 5% dextrose in water, borate-buffered saline containing trace metals or the like. Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial 25 surfaces, lubricants, fillers, stabilizers, etc. Methods of formulation are well known in the art and are disclosed, for example, in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co., Easton PA, which is incorporated herein by reference.

40 Pharmaceutical compositions for use within the present invention can be in the form of sterile, non-pyrogenic liquid solutions or suspensions, coated capsules, suppositories, 45 lyophilized powders, transdermal patches or other forms known in the art. Local administration may be by injection at the site of injury or defect, or by insertion or attachment of a solid carrier at the site, or by direct, topical application of a viscous 50 liquid, or the like. For local administration, the delivery vehicle preferably provides a

5 matrix for the growing bone or cartilage, and more preferably is a vehicle that can be absorbed by the subject without adverse effects.

10 Delivery of compounds herein to wound sites may be enhanced by the use of controlled-release compositions, such as those described in PCT publication
5 WO93/20859, which is incorporated herein by reference. Films of this type are particularly useful as coatings for prosthetic devices and surgical implants. The films may, for example, be wrapped around the outer surfaces of surgical screws, rods, pins,
15 plates and the like. Implantable devices of this type are routinely used in orthopedic surgery. The films can also be used to coat bone filling materials, such as hydroxyapatite
10 blocks, demineralized bone matrix plugs, collagen matrices and the like. In general, a film or device as described herein is applied to the bone at the fracture site. Application
20 is generally by implantation into the bone or attachment to the surface using standard surgical procedures.

25 In addition to the copolymers and carriers noted above, the biodegradable films and matrices may include other active or inert components. Of particular interest are those agents that promote tissue growth or infiltration, such as growth factors. Exemplary
30 growth factors for this purpose include epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), transforming growth factors (TGFs), parathyroid hormone (PTH), leukemia inhibitory factor (LIF), insulin-like
20 growth factors (IGFs) and the like. Agents that promote bone growth, such as bone morphogenetic proteins (U.S. Patent No. 4,761,471; PCT Publication WO90/11366), osteogenin (Sampath *et al. Proc. Natl. Acad. Sci. USA* (1987) 84:7109-13) and NaF
35 (Tencer *et al. J. Biomed. Mat. Res.* (1989) 23: 571-89) are also preferred. Biodegradable films or matrices include calcium sulfate, tricalcium phosphate, hydroxyapatite, polylactic
25 acid, polyanhydrides, bone or dermal collagen, pure proteins, extracellular matrix
40 components and the like and combinations thereof. Such biodegradable materials may be used in combination with non-biodegradable materials, to provide desired mechanical, cosmetic or tissue or matrix interface properties.

45 Alternative methods for delivery of compounds of the present invention include use of ALZET osmotic minipumps (Alza Corp., Palo Alto, CA); sustained release matrix
30 materials such as those disclosed in Wang *et al.* (PCT Publication WO90/11366); electrically charged dextran beads, as disclosed in Bao *et al.* (PCT Publication
50 WO92/03125); collagen-based delivery systems, for example, as disclosed in Ksander *et*

5 *al. Ann. Surg.* (1990) 211(3):288-94; methylcellulose gel systems, as disclosed in Beck *et*
10 *al. J. Bone Min. Res.* (1991) 6(11):1257-65; alginate-based systems, as disclosed in
5 Edelman *et al. Biomaterials* (1991) 12:619-26 and the like. Other methods well known in
the art for sustained local delivery in bone include porous coated metal prostheses that
can be impregnated and solid plastic rods with therapeutic compositions incorporated
within them.

15 The compounds of the present invention may also be used in conjunction with
agents that inhibit bone resorption. Antiresorptive agents, such as estrogen,
bisphosphonates and calcitonin, are preferred for this purpose. More specifically, the
10 compounds disclosed herein may be administered for a period of time (for instance,
months to years) sufficient to obtain correction of a bone deficit condition. Once the bone
20 deficit condition has been corrected, the vertebrate can be administered an anti-resorptive
compound to maintain the corrected bone condition. Alternatively, the compounds
disclosed herein may be administered with an anti-resorptive compound in a cyclical
25 15 manner (administration of disclosed compound, followed by anti-resorptive, followed by
disclosed compound, and the like).

30 In additional formulations, conventional preparations such as those described
below may be used.

35 Aqueous suspensions may contain the active ingredient in admixture with
20 pharmacologically acceptable excipients, comprising suspending agents, such as methyl
cellulose; and wetting agents, such as lecithin, lysolecithin or long-chain fatty alcohols.
The said aqueous suspensions may also contain preservatives, coloring agents, flavoring
agents, sweetening agents and the like in accordance with industry standards.

40 Preparations for topical and local application comprise aerosol sprays, lotions,
25 gels and ointments in pharmaceutically appropriate vehicles which may comprise lower
aliphatic alcohols, polyglycols such as glycerol, polyethylene glycol, esters of fatty acids,
oils and fats, and silicones. The preparations may further comprise antioxidants, such as
ascorbic acid or tocopherol, and preservatives, such as p-hydroxybenzoic acid esters.

45 Parenteral preparations comprise particularly sterile or sterilized products.

30 50 Injectable compositions may be provided containing the active compound and any of the
well known injectable carriers. These may contain salts for regulating the osmotic
pressure.

5 If desired, the osteogenic agents can be incorporated into liposomes by any of the reported methods of preparing liposomes for use in treating various pathogenic conditions. The present compositions may utilize the compounds noted above
10 incorporated in liposomes in order to direct these compounds to macrophages, monocytes, as well as other cells and tissues and organs which take up the liposomal composition. The liposome-incorporated compounds of the invention can be utilized by parenteral administration, to allow for the efficacious use of lower doses of the
15 compounds. Ligands may also be incorporated to further focus the specificity of the liposomes.

10 Suitable conventional methods of liposome preparation include, but are not limited to, those disclosed by Bangham, A.D. *et al. J Mol Biol* (1965) 23:238-252, Olson, F. *et al. Biochim Biophys Acta* (1979) 557:9-23, Szoka, F. *et al. Proc Natl Acad Sci USA* (1978) 75:4194-4198, Kim, S. *et al. Biochim Biophys Acta* (1983) 728:339:348, and Mayer, *et al. Biochim Biophys Acta* (1986) 858:161-168.

25 The liposomes may be made from the present compounds in combination with any of the conventional synthetic or natural phospholipid liposome materials including phospholipids from natural sources such as egg, plant or animal sources such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, sphingomyelin,
30 phosphatidylserine, or phosphatidylinositol and the like. Synthetic phospholipids that may also be used, include, but are not limited to: dimyristoylphosphatidylcholine, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine, and the corresponding synthetic
35 phosphatidylethanolamines and phosphatidylglycerols. Cholesterol or other sterols, cholesterol hemisuccinate, glycolipids, cerebroside, fatty acids, gangliosides, sphingolipids, 1,2-bis(oleoyloxy)-3-(trimethyl ammonio) propane (DOTAP), N-[1-(2,3-dioleoyl) propyl-N,N,N-trimethylammonium chloride (DOTMA), and other cationic
40 lipids may be incorporated into the liposomes, as is known to those skilled in the art. The relative amounts of phospholipid and additives used in the liposomes may be varied if desired. The preferred ranges are from about 60 to 90 mole percent of the phospholipid;
45 cholesterol, cholesterol hemisuccinate, fatty acids or cationic lipids may be used in amounts ranging from 0 to 50 mole percent. The amounts of the present compounds incorporated into the lipid layer of liposomes can be varied with the concentration of the
50 lipids ranging from about 0.01 to about 50 mole percent.

5 The liposomes with the above formulations may be made still more specific for
their intended targets with the incorporation of monoclonal antibodies or other ligands
specific for a target. For example, monoclonal antibodies to the BMP receptor may be
10 incorporated into the liposome by linkage to phosphatidylethanolamine (PE) incorporated
5 into the liposome by the method of Leserman, L. *et al. Nature* (1980) 288:602-604.

Veterinary uses of the disclosed compounds are also contemplated, as set forth
above. Such uses would include treatment of bone or cartilage deficits or defects
15 associated with hair or fur in domestic animals, livestock and thoroughbred horses.

The compounds of the present invention may be used to stimulate growth of bone-
10 forming cells or their precursors, or to induce differentiation of bone-forming cell
precursors, either *in vitro* or *ex vivo*. The compounds described herein may also modify a
20 target tissue or organ environment, so as to attract bone-forming cells to an environment
in need of such cells. As used herein, the term "precursor cell" refers to a cell that is
committed to a differentiation pathway, but that generally does not express markers or
25 function as a mature, fully differentiated cell. As used herein, the term "mesenchymal
cells" or "mesenchymal stem cells" refers to pluripotent progenitor cells that are capable
of dividing many times, and whose progeny will give rise to skeletal tissues, including
cartilage, bone, tendon, ligament, marrow stroma and connective tissue (see A. Caplan *J.*
30 *Orthop. Res.* (1991) 9:641-50). As used herein, the term "osteogenic cells" includes
20 osteoblasts and osteoblast precursor cells. More particularly, the disclosed compounds
are useful for stimulating a cell population containing marrow mesenchymal cells,
thereby increasing the number of osteogenic cells in that cell population. In a preferred
35 method, hematopoietic cells are removed from the cell population, either before or after
stimulation with the disclosed compounds. Through practice of such methods, osteogenic
25 cells may be expanded. The expanded osteogenic cells can be infused (or reinfused) into
a vertebrate subject in need thereof. For instance, a subject's own mesenchymal stem
cells can be exposed to compounds of the present invention *ex vivo*, and the resultant
osteogenic cells could be infused or directed to a desired site within the subject, where
40 further proliferation and/or differentiation of the osteogenic cells can occur without
45 immunorejection. Alternatively, the cell population exposed to the disclosed compounds
30 may be immortalized human fetal osteoblastic or osteogenic cells. If such cells are
infused or implanted in a vertebrate subject, it may be advantageous to "immunoprotect"

50

55

5 these non-self cells, or to immunosuppress (preferably locally) the recipient to enhance transplantation and bone or cartilage repair.

10 As stated above, the compounds of the present invention may also be used to stimulate the growth of hair either by enhancing its rate of formation from existing
5 follicles, stimulating inactive follicles, effecting the production of additional hair follicles or some combination of the foregoing, or by any other mechanism that may or may not presently be understood.

15 Within the present invention, an "effective amount" of a composition is that amount which produces a statistically significant effect. For example, an "effective
10 amount" for therapeutic uses is the amount of the composition comprising an active compound herein required to provide a clinically significant increase in healing rates in
20 fracture repair; reversal of bone loss in osteoporosis; reversal of cartilage defects or disorders; prevention or delay of onset of osteoporosis; stimulation and/or augmentation of bone formation in fracture non-unions and distraction osteogenesis; increase and/or
25 acceleration of bone growth into prosthetic devices; and repair of dental defects. An "effective amount" for uses in stimulating hair growth is that amount which provides the desired effect in terms of length or density of hair. Such effective amounts will be
30 determined using routine optimization techniques and are dependent on the particular condition to be treated, the condition of the patient, the route of administration, the
20 formulation, and the judgment of the practitioner and other factors evident to those skilled in the art. The dosage required for the compounds of the invention (for example, in
35 osteoporosis where an increase in bone formation is desired) is manifested as a statistically significant difference in bone mass between treatment and control groups. This difference in bone mass may be seen, for example, as a 5-20% or more increase in
25 bone mass in the treatment group. Other measurements of clinically significant increases in healing may include, for example, tests for breaking strength and tension, breaking
40 strength and torsion, 4-point bending, increased connectivity in bone biopsies and other biomechanical tests well known to those skilled in the art. General guidance for treatment regimens is obtained from experiments carried out in animal models of the
45 disease of interest. Differences between successfully treated subjects and controls with regard to stimulation of hair growth can generally be ascertained by direct observation.

50 The dosage of the compounds of the invention will vary according to the extent and severity of the need for treatment, the activity of the administered compound, the

5 general health of the subject, and other considerations well known to the skilled artisan.
Generally, they can be administered to a typical human on a daily basis as an oral dose of
about 0.1 mg/kg-1000 mg/kg, and more preferably from about 1 mg/kg to about 200
10 mg/kg. The parenteral dose will appropriately be 20-100% of the oral dose. While oral
5 administration may be preferable in most instances where the condition is a bone deficit
(for reasons of ease, patient acceptability, and the like), alternative methods of
administration may be appropriate for selected compounds and selected defects or
15 diseases. While topical administration is generally preferable for stimulating hair growth,
as generally only local effects are desired, systemic treatment may be preferable in some
10 instances as well.

20 Assays for Compounds Useful in the Invention

Assays for assessing the ability of a compound to inhibit proteasomal activity and
for inhibitors of NF- κ B activity are well known in the art. Two typical, but nonlimiting
25 15 assays are described below.

Assessment of Proteasomal Activity

Proteasomal activity is measured by an increase in cytoplasmic ubiquitinated
protein complexes, as assessed by Western blotting using an anti-ubiquitin antibody.

30 MG-63 cells are grown in confluency in alpha MEM media and 10% fetal calf
20 serum (FCS). Cells are then treated for 24 hours with specific compounds. Following the
indicated treatments, cells are scraped with a disposable scraper, washed twice with
phosphate saline solution (137 mM NaCl, 10 mM d-glucose, 4 mM KCl, 0.5 mM
35 Na₂HPO₄, 0.1 mM KH₂PO₄), centrifuged, and the resulting pellet is suspended in the
sample buffer containing 2% SDS, pH 6.75. The samples are heated and the
25 concentration of total protein calculated by means of Micro bicinchoninic acid (BCA)
40 Protein Assay Kit (Pierce, Rockford, IL/USA). The samples are diluted to obtain a final
protein concentration of 2 mg/ml, supplemented with 10% 2-mercaptoethanol, 1%
bromophenol blue and run on a 4-15% SDS-PAGE. Resulting gels are Western blotted
45 with anti-ubiquitin rabbit polyclonal antibody (diluted 1:100; Sigma, St. Louis,
30 MO/USA). The samples are visualized with horse-radish peroxidase coupled anti-rabbit
IgG antibodies (Amersham Corp., Arlington Heights, IL/USA) using ECL detection kits
(Amersham Corp.).

NF- κ B Activity Assays

Cells are treated with different concentrations of compounds, and nuclear extracts prepared. Briefly, cells are washed with phosphate-buffered saline, and resuspended in lysis buffer (0.6% Nonidet P-40, 150 mM NaCl, 10 mM Tris-HCl, pH 7.9, 1 mM EDTA, 0.5 mM DTT and a cocktail of protease inhibitors (Complete (TM), Boehringer Mannheim). After incubation on ice for 15 min, nuclei are collected by centrifugation. The pellet is resuspended in nuclear extraction buffer (10 mM Hepes, pH 7.9, 420 mM NaCl, 0.1 mM EDTA, 1.5 mM NgCl_2 , 0.5 mM DTT, protease inhibitors (Complete (TM), Boehringer Mannheim), 25% glycerol), and incubated at 4 degrees C for 30 min. The supernatant is collected and dialyzed in a buffer containing 10 mM TrisHCl, pH 7.5, 50 mM NaCl, 5 mM MgCl_2 , 1 mM EDTA, 1 mM DTT, and 20% glycerol. After dialysis, the nuclear extract is centrifuged to remove precipitated proteins, and aliquots are stored at -70 C. Protein concentration in the nuclear extracts is measured by the method of Bradford using a dye-binding assay kit (Bio-Rad).

The probe for electrophoretic mobility shift assays is a ^{32}P -labeled double-stranded oligonucleotide containing the consensus sequence specific for NF- κ B (Promega). Nuclear extracts (5 ug) are pre-incubated in 20- μ l reaction mixtures containing 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 2.5 mM DTT, 0.5 mM EDTA, 1 mM MgCl_2 , 4% glycerol, and 5 ug of poly (dI-dC). After 10 min at room temperature, 10-20 fmol of probe is added, and incubated further for 20 min. DNA-protein complexes are separated from free oligonucleotides on a 5% polyacrylamide/0.5X TBE gel (45 mM Tris-HCl, 45 mM boric acid, 1 mM EDTA). After electrophoresis, gels are dried and autoradiographed.

Assays for Production Inhibition

Compounds which inhibit the production of the enzymes having proteasomal activity or of NF- κ B can be assessed by measuring the level of production of these proteins in the presence and absence of candidate compounds. The levels of production can be readily measured in *in vitro* systems using, for example, immunoassays for the level of protein produced. The levels of such proteins can also be assessed by utilizing, for example, methionine labeling and size separation of proteins in the cells to be assessed. In order to effect a convenient level of protein production for measurement, it

5 is advantageous to use recombinant expression systems for the relevant enzymes or the NF- κ B so that substantial amounts are produced.

10 Typical approaches to inhibiting the production of NF- κ B or proteasome enzymes include the use of antisense technology or formation of triplexes with double-stranded
5 forms of nucleotide sequences relevant in the expression of the genes. In addition, various small molecules may also inhibit this production.

15 Screening Assays - Bone

The osteogenic activity of the compounds used in the methods of the invention
10 can be verified using *in vitro* screening techniques, such as the assessment of transcription of a reporter gene coupled to a bone morphogenetic protein-associated promoter or in
20 alternative assays.

ABA Screening Assay

25 15 A rapid throughput screening test for compounds that stimulate bone formation by demonstration that they are capable of stimulating expression of a reporter gene linked to a BMP promoter (a surrogate for the production of bone morphogenetic factors that are endogenously produced) is described in U.S. Application Serial No. 08/458,434, filed 2
30 June 1995, the entire contents of which are incorporated herein by reference. This assay
20 is also described as a portion of a study of immortalized murine osteoblasts (derived from a mouse expressing a transgene composed of a BMP2 promoter driving expression of T-antigen) in Ghosh-Choudhery, N. *et al. Endocrinology* (1996) 137:331-39. In this study,
35 the immortalized cells were stably transfected with a plasmid containing a luciferase reporter gene driven by a mouse BMP2 promoter (-2736/114 bp), and responded in a
25 dose-dependent manner to recombinant human BMP2.

40 Briefly, the assay utilizes cells transformed permanently or transiently with constructs in which the promoter of a bone morphogenetic protein, specifically BMP2 or BMP4, is coupled to a reporter gene, typically luciferase. These transformed cells are
45 then evaluated for the production of the reporter gene product; compounds that activate
30 the BMP promoter will drive production of the reporter protein, which can be readily assayed. Many thousands of compounds have been subjected to this rapid screening technique, and only a very small percentage are able to elicit a level of expression of
50 reporter gene 5-fold greater than that produced by vehicle. Compounds that activate the

5 BMP promoter fall into groups, where members of each group share certain structural
characteristics not present in inactive compounds. The active compounds ("BMP
10 promoter-active compounds" or "active compounds") are useful in promoting bone or
cartilage growth, and thus in the treatment of vertebrates in need of bone or cartilage
5 growth.

BMP promoter-active compounds can be examined in a variety of other assays
that test specificity and toxicity. For instance, non-BMP promoters or response elements
15 can be linked to a reporter gene and inserted into an appropriate host cell. Cytotoxicity
can be determined by visual or microscopic examination of BMP promoter- and/or non-
10 BMP promoter-reporter gene-containing cells, for instance. Alternatively, nucleic acid
and/or protein synthesis by the cells can be monitored. For *in vivo* assays, tissues may be
20 removed and examined visually or microscopically, and optionally examined in
conjunction with dyes or stains that facilitate histologic examination. In assessing *in vivo*
assay results, it may also be useful to examine biodistribution of the test compound, using
25 15 conventional medicinal chemistry/animal model techniques.

Neonatal Mouse Calvaria Assay (*In vitro*)

30 An assay for bone resorption or bone formation is similar to that described by
Gowen M. & Mundy G. *J Immunol* (1986) 136:2478-82. Briefly, four days after birth,
20 the front and parietal bones of ICR Swiss white mouse pups are removed by
microdissection and split along the sagittal suture. In an assay for resorption, the bones
are incubated in BGJb medium (Irvine Scientific, Santa Ana, CA) plus 0.02% (or lower
35 concentration) β -methylcyclodextrin, wherein the medium also contains test or control
substances. The medium used when the assay is conducted to assess bone formation is
25 Fitton and Jackson Modified BGJ Medium (Sigma) supplemented with 6 μ g/ml insulin,
40 6 μ g/ml transferrin, 6 ng/ml selenous acid, calcium and phosphate concentrations of 1.25
and 3.0 mM, respectively, and ascorbic acid to a concentration of 100 μ g/ml is added
every two days. The incubation is conducted at 37°C in a humidified atmosphere of 5%
45 CO₂ and 95% air for 96 hours.

30 Following this, the bones are removed from the incubation media and fixed in
10% buffered formalin for 24-48 hours, decalcified in 14% EDTA for 1 week, processed
through graded alcohols; and embedded in paraffin wax. Three μ m sections of the
50

5 calvaria are prepared. Representative sections are selected for histomorphometric
assessment of bone formation or bone resorption. Bone changes are measured on sections
cut 200 μ m apart. Osteoblasts and osteoclasts are identified by their distinctive
10 morphology.

5 Other auxiliary assays can be used as controls to determine non-BMP promoter-
mediated effects of test compounds. For example, mitogenic activity can be measured
using screening assays featuring a serum-response element (SRE) as a promoter and a
15 luciferase reporter gene. More specifically, these screening assays can detect signaling
through SRE-mediated pathways, such as the protein kinase C pathway. For instance, an
10 osteoblast activator SRE-luciferase screen and an insulin mimetic SRE-luciferase screen
are useful for this purpose. Similarly, test compound stimulation of cAMP response
20 element (CRE)-mediated pathways can also be assayed. For instance, cells transfected
with receptors for PTH and calcitonin (two bone-active agents) can be used in CRE-
luciferase screens to detect elevated cAMP levels. Thus, the BMP promoter specificity of
25 a test compound can be examined through use of these types of auxiliary assays.

In vivo Assay of Effects of Compounds on Murine Calvarial Bone Growth

30 Male ICR Swiss white mice, aged 4-6 weeks and weighing 13-26 gm, are
employed, using 4-5 mice per group. The calvarial bone growth assay is performed as
20 described in PCT application WO95/24211, incorporated by reference. Briefly, the test
compound or appropriate control vehicle is injected into the subcutaneous tissue over the
35 right calvaria of normal mice. Typically, the control vehicle is the vehicle in which the
compound was solubilized, and is PBS containing 5% DMSO or is PBS containing
Tween (2 μ l/10 ml). The animals are sacrificed on day 14 and bone growth measured by
25 histomorphometry. Bone samples for quantitation are cleaned from adjacent tissues and
40 fixed in 10% buffered formalin for 24-48 hours, decalcified in 14% EDTA for 1-3 weeks,
processed through graded alcohols; and embedded in paraffin wax. Three to five μ m
sections of the calvaria are prepared, and representative sections are selected for
45 histomorphometric assessment of the effects on bone formation and bone resorption.
30 Sections are measured by using a camera lucida attachment to trace directly the
microscopic image onto a digitizing plate. Bone changes are measured on sections cut
200 μ m apart, over 4 adjacent 1x1 mm fields on both the injected and noninjected sides of
50

the calvaria. New bone is identified by its characteristic woven structure, and osteoclasts and osteoblasts are identified by their distinctive morphology. Histomorphometry software (OsteoMeasure, Osteometrix, Inc., Atlanta) is used to process digitizer input to determine cell counts and measure areas or perimeters.

Typical treatment regimens for testing utilize application of the compound to be tested over several days of repeated administration.

Additional *In Vivo* Assays - Bone

Lead compounds can be further tested in intact animals using an *in vivo*, dosing assay. Prototypical dosing may be accomplished by subcutaneous, intraperitoneal or oral administration, and may be performed by injection, sustained release or other delivery techniques. The time period for administration of test compound may vary (for instance, 28 days as well as 35 days may be appropriate). An exemplary, *in vivo* oral or subcutaneous dosing assay may be conducted as follows:

In a typical study, 70 three-month-old female Sprague-Dawley rats are weight-matched and divided into seven groups, with ten animals in each group. This includes a baseline control group of animals sacrificed at the initiation of the study; a control group administered vehicle only; a PBS-treated control group; and a positive control group administered a compound (non-protein or protein) known to promote bone growth. Three dosage levels of the compound to be tested are administered to the remaining three groups.

Briefly, test compound, positive control compound, PBS, or vehicle alone is administered subcutaneously once per day for 35 days. All animals are injected with calcein nine days and two days before sacrifice (two injections of calcein administered each designated day). Weekly body weights are determined. At the end of the 35-day cycle, the animals are weighed and bled by orbital or cardiac puncture. Serum calcium, phosphate, osteocalcin, and CBCs are determined. Both leg bones (femur and tibia) and lumbar vertebrae are removed, cleaned of adhering soft tissue, and stored in 70% ethanol for evaluation, as performed by peripheral quantitative computed tomography (pQCT; Ferretti, J. *Bone* (1995) 17:353S-64S), dual energy X-ray absorptiometry (DEXA; Laval-Jeantet A. *et al. Calcif Tissue Intl* (1995) 56:14-18; J. Casez *et al. Bone and Mineral* (1994) 26:61-68) and/or histomorphometry. The effect of test compounds on bone remodeling can thus be evaluated.

5 Lead compounds can also be tested in acute ovariectomized animals (prevention model) using an *in vivo* dosing assay. Such assays may also include an estrogen-treated group as a control. An exemplary subcutaneous dosing assay is performed as follows:

10 In a typical study, 80 three-month-old female Sprague-Dawley rats are weight-
5 matched and divided into eight groups, with ten animals in each group. This includes a baseline control group of animals sacrificed at the initiation of the study; three control groups (sham ovariectomized (sham OVX) + vehicle only; ovariectomized (OVX) + vehicle only; PBS-treated OVX); and a control OVX group that is administered a
15 compound known to promote bone growth. Three dosage levels of the compound to be
10 tested are administered to the remaining three groups of OVX animals.

20 Since ovariectomy (OVX) induces hyperphagia, all OVX animals are pair-fed with sham OVX animals throughout the 35 day study. Briefly, test compound, positive control compound, PBS, or vehicle alone is administered orally or subcutaneously once per day for 35 days. Alternatively, test compound can be formulated in implantable
25 pellets that are implanted for 35 days, or may be administered orally, such as by gastric
15 gavage. All animals, including sham OVX/vehicle and OVX/vehicle groups, are injected intraperitoneally with calcein nine days and two days before sacrifice (two injections of calcein administered each designated day, to ensure proper labeling of newly formed
30 bone). Weekly body weights are determined. At the end of the 35-day cycle, the
20 animals' blood and tissues are processed as described above.

 Lead compounds may also be tested in chronic OVX animals (treatment model).
35 An exemplary protocol for treatment of established bone loss in ovariectomized animals that can be used to assess efficacy of anabolic agents may be performed as follows. Briefly, 80 to 100 six month old female, Sprague-Dawley rats are subjected to sham
25 surgery (sham OVX) or ovariectomy (OVX) at time 0, and 10 rats are sacrificed to serve as baseline controls. Body weights are recorded weekly during the experiment. After
40 approximately 6 weeks (42 days) or more of bone depletion, 10 sham OVX and 10 OVX rats are randomly selected for sacrifice as depletion period controls. Of the remaining
45 animals, 10 sham OVX and 10 OVX rats are used as placebo-treated controls. The
30 remaining OVX animals are treated with 3 to 5 doses of test drug for a period of 5 weeks (35 days). As a positive control, a group of OVX rats can be treated with an agent such as PTH, a known anabolic agent in this model (Kimmel *et al. Endocrinology* (1993)
50 132:1577-84). To determine effects on bone formation, the following procedure can be

5 followed. The femurs, tibiae and lumbar vertebrae 1 to 4 are excised and collected. The proximal left and right tibiae are used for pQCT measurements, cancellous bone mineral density (BMD) (gravimetric determination), and histology, while the midshaft of each
10 tibiae is subjected to cortical BMD or histology. The femurs are prepared for pQCT
5 scanning of the midshaft prior to biomechanical testing. With respect to lumbar vertebrae (LV), LV2 are processed for BMD (pQCT may also be performed); LV3 are prepared for undecalcified bone histology; and LV4 are processed for mechanical testing.

15 Assays - Hair Growth: *In Vivo* Assay of Effects of Compounds on Hair Follicles


10 Proliferation and Hair Growth

20 The assay described above to assess the effect of compounds on calvarial bone growth can also be used to assess the ability of compounds to stimulate hair growth. The test compound or appropriate control vehicle is applied to the upper and lower back of male ICR Swiss white mice either topically or by subcutaneous injection. The vehicle is
25 selected as appropriate for the compound to be tested and for the route of administration. Optionally, the hair in the test area may be removed prior to administration. After a suitable interval, typically 7 days, the mice are anesthetized and a biopsy of the dorsal treatment area is taken using a 6 mm dermal punch. The specimens are fixed in 10%
30 buffered formalin and imbedded in paraffin wax, and sectioned and stained to observe
20 hair follicles. In addition, photography can be used to observe and record hair growth; typically such growth is observed after 14-18 days. After a suitable interval, typically 21
35 days, the animals may be euthenized and the hair analyzed for fiber analysis and the tissue from the treatment area analyzed for quantitation of hair follicles.

25 Nature of the Compounds Useful in the Invention

40 The compounds useful in the methods and compositions of the invention are inhibitors of proteasomal activity, of the transcription factor NF- κ B, preferably both. Known inhibitors of these activities can be ascertained from the literature or compounds
45 can be tested for these activities using assays known in the art. In addition, inhibitors
30 which lower the level of effective expression of the nucleotide sequence encoding the enzymes that have proteasomal activity or of the nucleotide sequence encoding NF- κ B can be assessed and used in the invention methods.

The compounds thus identified, which are used according to the method of the invention as it relates to treating bone defects, however, preferably do not include compounds that inhibit the isoprenoid pathway, such as the statins. A description of these excluded compounds can be found in WO98/25460 and in U.S. Serial No. 09/096,631, both cited above and incorporated herein by reference. For convenience, the isoprenoid pathway referred to is set forth herein in Figure 2. One class of compounds which are inhibitors are the statins which have the formula







wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6C;

Y represents one or more carbocyclic or heterocyclic rings wherein, when Y comprises two or more rings, said rings may be fused; and

R' represents a cation, H or a substituted or unsubstituted alkyl group of 1-6C; and the dotted lines represent optional π -bonds.

These compounds may, however, be used in the method of the invention as it relates to the stimulation of hair growth.

Compounds known to be proteasome or NF-κB inhibitors include:

| Proteasome Inhibitors | |
|-------------------------|---|
| PSI | N-carbobenzoyl-Ile-Glu-(OtBu)-Ala-Leu-CHO |
| MG-132 | N-carbobenzoyl-Leu-Leu-Leu-CHO |
| MG-115 | N-carbobenzoyl-Leu-Leu-Nva-CHO |
| MG-101 or Calpain Inh I | N-Acetyl-Leu-Leu-norLeu-CHO |
| ALLM | N-Acetyl-Leu-Leu-Met-CHO |
| | N-carbobenzoyl-Gly-Pro-Phe-Leu-CHO |
| | N-carbobenzoyl-Gly-Pro-Ala-Phe-CHO |
| | N-carbobenzoyl-Leu-Leu-Phe-CHO |
| | N-carbobenzoyl-Leu-Ala-Leu-CHO |
| Gliotoxin |  |
| SN50 | NLS of NF-κB MW 2781 |
| Bay 11-7082 |  |
| Capsaicin |  |
| PDTC |  |

See, for example, Vinitsky, A. *et al. J Biol Chem* (1994) 269:29860-29866;
 Figueiredo-Pereira, M.E. *et al. J Neurochem* (1994) 63:1578-1581; Wojcik, C. *et al. Eur*
J Cell Biol (1996) 71:311-318.

In the foregoing list, lactacystin is known to be an irreversible inhibitor of
 proteasome activity. It binds to the β catalytic subunit and is a specific inhibitor of the
 20S proteasome. It also irreversibly inhibits NF-κB.

SN50 is the NLS (nuclear localization sequence) of p50 plus the hydrophobic
 region of K-FGF. It inhibits the translocation of the NF-κB active complex to the
 nucleus.

Certain peptidyl epoxy ketones such as EST are irreversible inhibitors of the
 proteasomes. MG-132 shows activity against the chymotryptic activity of the 20S protein

without affecting its ATPase or isopeptidase activity and reversibly inhibits NF- κ B activity. MG-115 and MG-341 show similar activities to MG-132. Various other inhibitors of NF- κ B are less active in the ABA assay. These include capsaicin, curcumin, and resiniferatoxin. Other compounds known to inhibit NF- κ B are gliotoxin and PDTC (1-pyrrolidine carbothiotic acid). Various other compounds such as BAY-11-7082 and BAY-11-7085 as well as calyculin-A inhibit phosphorylation of NF- κ B. Calpain inhibitor inhibits calpain 1 and the proteasome; other compounds such as olomoucine and roscovitine inhibit cdk2 and/or cdk5.

An additional compound shown to be a proteasome inhibitor is pentoxifylline (PTX). Combaret. L. et al. Mol Biol Rep (1999) 26:95-101. It is active in the in vitro calvarial assay described above.


As set forth above, in preferred embodiments of the methods of the invention, the identified compounds used in treatment of bone disorders are other than statins and other compounds that inhibit the isoprenoid pathway, typically as shown in Figure 1. In other preferred embodiments, also excluded from use in the methods of treatment of bone disorders of the present invention, are compounds described in PCT applications WO98/17267, WO97/15308, and WO97/48694 cited and incorporated herein by reference hereinabove. However, the use of these compounds in the method to stimulate hair growth according to the invention is not excluded.

The following examples are intended to illustrate but not to limit the invention.

Example 1

High Throughput Screening

Thousands of compounds have been tested in the assay system set forth in U.S. Serial No. 08/458,434, filed 2 June 1995, and incorporated herein by reference. Representative compounds of the invention gave positive responses, while the majority of (unrelated) compounds are inactive. In this screen, the standard positive control was the compound 59-0008 (also denoted "OS8"), which is of the formula:



In more detail, the 2T3-BMP-2-LUC cells, a stably transformed osteoblast cell line described in Ghosh-Choudhury *et al. Endocrinology* (1996) 137:331-39, referenced above, was employed. The cells were cultured using α -MEM, 10% FCS with 1% penicillin/streptomycin and 1% glutamine ("plating medium"), and were split 1:5 once per week. For the assay, the cells were resuspended in a plating medium containing 4% FCS, plated in microtiter plates at a concentration of 5×10^3 cells (in 50 μ l)/well, and incubated for 24 hours at 37°C in 5% CO₂. To initiate the assay, 50 μ l of the test compound or the control in DMSO was added at 2X concentration to each well, so that the final volume was 100 μ l. The final serum concentration was 2% FCS, and the final DMSO concentration was 1%. Compound 59-0008 (10 μ M) was used as a positive control.

The treated cells were incubated for 24 hours at 37°C and 5% CO₂. The medium was then removed, and the cells were rinsed three times with PBS. After removal of excess PBS, 25 μ l of 1X cell culture lysing reagent (Promega #E153A) was added to each well and incubated for at least ten minutes. Optionally, the plates/samples could be frozen at this point. To each well was added 50 μ l of luciferase substrate (Promega #E152A; 10 ml Promega luciferase assay buffer per 7 mg Promega luciferase assay substrate). Luminescence was measured on an automated 96-well luminometer, and was expressed as either picograms of luciferase activity per well or as picograms of luciferase activity per microgram of protein.

In this assay, compound 59-0008 (3-phenylazo-1H-4,1,2-benzothiadiazine) exhibits a pattern of reactivity which is maximal at a concentration of approximately 3-10 μ M. Accordingly, other tested compounds can be evaluated at various concentrations, and the results compared to the results obtained for 59-0008 at 10 μ M (which value would be normalized to 100). Alternatively, the reactivity of a compound to be tested can be compared directly to a negative control containing no compound.

The control compound 59-0328, which is simvastatin, gives a good response. The known proteasome inhibitors MG-132 and MG-115 also show high activity; MG-132 is

effective at lower concentrations. Positive responses are also obtained using lactacystin. However, gliotoxin, olomoucine, roscovitine, SN50, PDTC, and capsaicin do not give promising responses.

Example 2

In vitro Bone Formation

Selected compounds and appropriate controls were assayed *in vitro* (*ex vivo*) for bone formation activity (described above in "Techniques for Neonatal Mouse Calvaria Assay (*in vitro*)). Histomorphometrical assessments of *ex vivo* calvaria were carried out using an OsteoMetrics bone morphometry measurement program, according to the manufacturer's instructions. Measurements were determined using either a 10- or 20-fold objective with a standard point counting eyepiece graticule.

New bone formation was determined (using a 10X objective) by measuring the new bone area formed in one field in 3 representative sections of each bone (4 bones per group). Each measurement was carried out ½ field distance from the end of the suture. Both total bone and old bone area were measured. Data were expressed as new bone area in μm^2 .

The results in Example 1 were somewhat imperfectly correlated with the results in this assay. The control compound, simvastatin showed new bone formation in this assay as did MG-132 and lactacystin. MG-115 also showed positive results although less dramatic than those of simvastatin. However, gliotoxin, which appeared negative in the ABA assay of Example 1 did demonstrate the ability to stimulate bone growth. The remaining compounds, olomoucine, roscovitine, SN50, PDTC and capsaicin appeared negative in this assay.

Osteoblast numbers are determined by point counting. The number of osteoblast cells lining the bone surface on both sides of the bone are counted in one field using a 20X objective. Data are expressed as osteoblast numbers/mm of bone surface.

Alkaline phosphatase activity is measured in the conditioned media of the murine organ cultures, using the method described by Majeska, R.J. *et al. Exp Cell Res* (1978) 111:465-465. Conditioned media are incubated at 37°C for 20 minutes with phosphatase substrate 104 (Sigma) and the reaction stopped with 2 ml of 0.1 M NaOH. Alkaline phosphatase activity is calculated by measuring cleaved substrate at an optical density of

410 nm in a Beckman dual beam spectrophotometer from the OD410 and corrected for protein concentration.

PSI and MG-132 and control compounds/factors bFGF and BMP-2, and a vehicle control were tested in this assay and the calvaria were analyzed histomorphometrically, as described above. Increase in bone area as a function of concentration; the increase in osteoblasts and the enhancement of alkaline phosphatase activity for PSI were measured.

The data show that PSI is as good as, or better than, BMP-2 and bFGF (two "gold standard" agents for bone growth; see Wozney J. *Molec Reprod Dev* (1992) 32:160-67; WO95/24211) for inducing bone formation.

An additional experiment, pentoxifylline (PTX) was tested in the foregoing assay. It exhibited the ability to enhance new bone formation in concentrations as low as 0.1 μM . At a concentration of 10 μM , PTX appeared to enhance the new bone area over control by over 100%; at 100 μM , the increase was approximately three (3) times that of control.

Example 3

In vivo Calvarial Bone Growth Data

PSI and MG-132 were assayed *in vivo* according to the procedure described previously (see "*In vivo* Assay of Effects of Compounds on Murine Calvarial Bone Growth", *supra*). As a control, simvastatin provided a 1.5 fold increase in the number of osteoblasts.

In one experiment, vehicle control, bFGF and varying doses of PSI were tested in the *in vivo* calvarial bone growth assay. The results are reported as a measurement of total bone area, % increase in area over vehicle control, and % increase in new bone width as shown below.

| Compound | Total Bone Area (μm^2) | % Increase* in Bone Area Compared with Control | % Increase* in New Bone Width |
|---------------|-------------------------------------|--|-------------------------------|
| Control | 0.64 \pm 0.03 | | |
| 0.1 mg/kg/day | 0.74 \pm 0.02 | 21.7 \pm 3.5 | |
| 1 mg/kg/day | 0.83 \pm 0.02 | 35.4 \pm 3.4 | 19.9 \pm 2.0 |
| 5 mg/kg/day | 0.79 \pm 0.03 | 32.1 \pm 5.6 | 19.9 \pm 4.4 |
| | | *p < 0.05 | *p < 0.001 |






In addition, histological examination showed confirmation of bone growth both when 5 mg/kg/day of PSI was used and 1 mg/kg/day was used.








Example 4

Summary of Effects on Bone Formation

The table below summarizes the results obtained for compounds tested in the various assays set forth above. It is seen that compounds that are proteasome inhibitors also enhance bone formation. In the compounds tested in this table, however, compounds which are known to be inhibitors only of NF-κB but which fail to inhibit proteasomal activity, do not enhance luciferase activity (indicative of BMP-2 promoter activity) in the high through-put assay, nor do they enhance bone formation in the calvarial assay *in vitro*, to as great an extent as do proteasome inhibitors.

Compounds useful in the invention include:

| Compound | Structure | | Luciferase Activity (ED ₅₀ -μM) | | Bone Formation (ED ₅₀ -μM) | | Proteasome Activity (ED ₅₀ -μM) |
|-------------|---|---|--|---|---------------------------------------|---|--|
| Simvastatin |  | ↑ | 0.2 | ↑ | 0.2 | ↓ | - |
| Lactacystin |  | ↑ | 1 | ↑ | 1 | ↓ | 1.5 |
| PS1 | Z-lie-Glu(OtBu)-Ala-Leu-CHO | ↑ | 0.05 | ↑ | 0.03 | ↓ | 0.035 |
| MG132 |  Z-Leu-Leu-Leu-CHO | ↑ | 0.25 | ↑ | 0.5 | ↓ | 0.3 |
| MG262 |  | ↑ | 0.1 | ↑ | 0.1 | ↓ | 0.07 |
| MG115 |  Z-Leu-Leu-Nva-CHO | ↑ | 2 | ↑ | 1 | ↓ | 1 |

| Compound | Structure | | Luciferase Activity (ED ₅₀ -μM) | | Bone Formation (ED ₅₀ -μM) | | Proteasome Activity (ED ₅₀ -μM) |
|---------------|--|---|--|---|---|---|--|
| ALLN |  N-Acetyl-Leu-Leu-Nle- CHO | ↑ | 10 | - | - | ↓ | 1.5 |
| Cyclosporin A |  | - | - | ↑ | 10 | ↓ | 1.0 |
| Gliotoxin |  | - | - | ↑ | 10 | - | - |
| SN50 | NLS of NF-KB MW 2781 | - | - | - | - | - | - |
| ALLM | N-Acetyl-Leu-Leu-Meth- CHO | - | - | - | - | ↓ | 4 |
| PPM-18 |  | - | - | - | - | - | - |
| Bay 11-7082 |  | - | - | - | - | - | - |
| Capsaicin |  | - | - | - | - | ↓ | 30 |
| PDTC |  | - | - | - | - | - | - |

Example 5Effect of PSI and Other Proteasome Inhibitors on Hair Follicle Production

The *in vivo* bone calvarial growth assay of Example 3 was modified to observe the number of hair follicles in treated mice. In initial observations, PSI (5mg/kg/day) was injected three times a day for 5 days over the calvaria of Swiss ICR mice as described above. Sixteen days later the mice were sacrificed. Histology of the calvaria revealed a strikingly large increase in the number of hair follicles in those mice treated with PSI versus control mice. In addition to PSI, MG132 (10mg/kg), MG115 (10mg/kg) and lactacysin administered in the same way also stimulated an increase in the number of hair follicles.

Example 6Stimulation of Hair Growth

Male Swiss ICR mice were first treated to remove hair from the scalp and dorsal regions as follows. Paraffin wax was liquefied by heating to 55°C and the liquefied wax then applied by brush to the scalp and/or back (under anesthesia). The wax was allowed to solidify and then removed. The day following hair stripping, PSI (1 mg/kg/day) was injected subcutaneously three times a day for five days into the scalp and dorsal region. On day 7 a dermal punch biopsy was taken; histology revealed a large increase in the number of hair follicles in mice administered PSI versus control mice. By day 18, it was observable that the treated mice had a hair growth rate greater than that of the mice in the control group.

The mice were sacrificed on day 21 and histology was performed on the dermis of the scalp and of the dorsal region. In the treated mice, mature hair follicles in numbers much greater than in controls had migrated to the lower region of the dermis. Upon closer examination, it was observed that mice that had received only vehicle had quiescent hair follicles. When treated with PSI such follicles were stimulated to differentiate into mature hair follicles and to migrate to the lower region of the dermis.

Example 7Topical Administration

PSI was prepared as a topical formulation, where the vehicle was 50% propylene glycol, 30% ethanol, 20% deionized water, at 0.1% concentration of PSI. The solution

5 was applied 3 times a day for 5 days. The mice in a treated group were observed as compared to controls similarly treated with vehicle alone. The results at day 16 showed stimulation of hair growth relative to the controls.

10 In addition to stimulating hair growth, PSI was able to thicken both the hair and the hair shaft. PSI increases hair count when the follicle area is greater than 0.01 mm^2 .
5 When the protocol above was repeated using a 0.5% solution of PSI in groups containing 5 mice each, the number of hairs per 0.8 mm^2 was 60 in the treated mice versus about 10
15 in the control group. The percentage of follicle area in a region of about 0.8 mm^2 was about 30% as an average in the treated group as compared to 15% as an average in the
20 control group.

20 Example 8

Dose Requirements

25 In order to determine the minimal effective dosage of PSI, when used topically, a dose response curve for PSI was prepared. All experiments were performed according to current good laboratory practice regulations (21CFR58). The mice were divided into 7
30 groups, 10 mice each, wherein one group was control treated only with vehicle and groups 1-6 with a series of increasing concentrations of PSI in a vehicle comprising 50% propylene glycol, 30% ethanol, 20% deionized water. The concentrations were 0.006%,
20 0.012%, 0.025%, 0.05%, 0.1% and 0.5%.

35 The mice were anesthetized (50 μl Mouse Cocktail containing 3 ml ketamine, 2 ml small animal rompum, 5 ml NaCl), identified by ear punch code, weighed and the hair on the dorsal side removed by waxing as described in Example 6. After waxing, the animals were photographed. On the following day (day 1), 100 μl of PSI at the above
25 concentrations in vehicle was brushed onto the area of removed hair. A similar application of PSI solution was performed daily for an additional 4 days.

40 On Day 7 mice were anesthetized and a biopsy of the dorsal treatment area taken using a 6 mm dermal punch; the specimens were fixed in 10% buffered formalin and embedded in paraffin wax. Sections were cut using a standard microtome.

45 Mice were monitored daily for signs of hair growth, and any hair growth was recorded by photography. On day 21 animals were euthanized (75mg/kg body weight phenobarbital, IP injection), 2 cm hair samples were taken for optical based fiber analysis,
50 and the remaining dorsal treatment area was fixed in 10% buffered formalin for further

5 histological analysis. Analysis included quantification of hair thickness and
quantification of mature hair follicles. Results were expressed as the mean = +/- the
standard error of the mean. Data were analyzed by repeated measures of analysis of
10 variance followed by the Tukey-Kramer post test P values of <0.05 were considered
5 significant.

The results indicate that the minimal effective dose of PSI is 0.5% applied 1 time
a day for 4 days; additional experiments showed that 0.1% of PSI applied topically 3
15 times a day for 5 days was also effective.

Gross observation of mice receiving an effective dose indicated an enhanced rate
10 of hair growth, a thickening of hair diameter, increase in sheath diameter, and
differentiation of quiescent hair follicles into more mature forms.

20 The contents of all documents cited above are expressly incorporated herein to the
extent required to understand the invention.

From the foregoing, it will be appreciated that, although specific embodiments of
25 the invention have been described herein for purposes of illustration, various
modifications may be made without deviating from the spirit and scope of the invention.
Accordingly, the invention is not limited except as by the appended claims.

Claims

5

10

15

20

25

30

35

40

45

50

55

Claims

1. A method to enhance bone formation or to treat pathological dental conditions or to treat degenerative joint conditions in a vertebrate animal which method comprises administering to a vertebrate subject in need of such treatment an effective amount of a compound that inhibits the activity of NF- κ B or that inhibits proteasomal activity or that inhibits production of proteasome proteins.
2. The method of claim 1 wherein said compound inhibits proteasomal activity or that inhibits production of proteasomal proteins.
3. The method of claim 1 wherein said compound does not inhibit the isoprenoid pathway.
4. The method of claim 1 wherein said compound is lactacystin, a peptidyl aldehyde, or PTX.
5. The method of claim 1 wherein said subject is characterized by a condition selected from the group consisting of osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation.
6. The method of claim 1 which further comprises administering to said subject one or more agents that promote bone growth or that inhibit bone resorption.
7. The method of claim 6 wherein said agents are selected from the group consisting of bone morphogenetic factors, anti-resorptive agents, osteogenic factors, cartilage-derived morphogenetic proteins, growth hormones, estrogens, bisphosphonates, statins and differentiating factors.
8. A method to treat a mammalian subject for a condition benefited by stimulating hair growth which method comprises administering to said mammalian

5 subject in need of such treatment an effective amount of a compound that inhibits the
activity of NF- κ B or that inhibits proteasomal activity or that inhibits production of these
proteins.

10 9. The method of claim 8 wherein said compound inhibits proteasomal
activity or that inhibits production of proteasome proteins.

15 10. The method of claim 9 wherein said compound is lactacystin or a peptidyl
aldehyde.

10 11. A pharmaceutical composition for treating bone disorders, dental
20 pathological conditions or degenerative joint conditions which composition comprises a
compound that inhibits the activity of NF- κ B or that inhibits proteasomal activity or that
inhibits production of these proteins.

25 12. The pharmaceutical composition of claim 11 wherein said compound
inhibits proteasomal activity or that inhibits production of proteasomal proteins.

30 13. The pharmaceutical composition of claim 11 wherein said compound does
20 not inhibit the isoprenoid pathway.

35 14. The pharmaceutical composition of claim 11 wherein said compound is
lactacystin, a peptidyl aldehyde, or PTX.

25 15. The pharmaceutical composition of claim 11 wherein said compound does
40 not inhibit the isoprenoid pathway.

45 16. A pharmaceutical composition for treating for a condition benefited by
stimulating hair growth which composition comprises a compound that inhibits the
30 activity of NF- κ B or that inhibits proteasomal activity or that inhibits production of these
proteins.

50

55

5 17. The pharmaceutical composition of claim 13 wherein said compound is
lactacystin or a peptidyl aldehyde.

10 18. A method to identify a compound which enhances bone growth or
5 stimulates hair growth which method comprises subjecting said compound to an assay for
determining its ability to inhibit NF- κ B activity, whereby a compound which inhibits the
activity of NF- κ B is identified as a compound which enhances bone growth; or
15 subjecting said compound to an assay for determining its ability to inhibit the
production of NF- κ B, whereby a compound which inhibits the production of NF- κ B is
10 identified as a compound which enhances bone growth; or
20 subjecting a candidate compound to an assay to assess its ability to inhibit
proteasomal activity, whereby a compound which inhibits proteasomal activity is
identified as a compound that enhances bone growth; or
25 subjecting a candidate compound to an assay to assess its ability to inhibit the
15 production of enzymes with proteasomal activity, whereby a compound which inhibits the
production of enzymes with proteasomal activity is identified as a compound that
enhances bone growth.

1/1




Figure 1